Breakthrough Drug alphaCT1 Could Revolutionize Surgical Scar Healing

FirstString Research Inc., a biopharmaceutical company, has secured $55 million in funding since 2018 to develop alphaCT1. The molecule aims to improve the appearance of surgical scars, a common issue affecting millions of patients yearly in the US. Over 300 million surgical procedures take place in the United States annually, often leaving patients with noticeable scars. AlphaCT1 works by influencing fibroblasts, the cells responsible for producing collagen. These cells stretch and change direction under the drug’s effect, leading to better scar formation.

In untreated scars, collagen forms stiff, parallel strips, reducing tissue flexibility. Scars treated with alphaCT1, however, develop a collagen structure closer to unwounded skin. This improvement was confirmed in Phase II clinical trials, where treated scars showed long-term aesthetic benefits compared to controls. The results were published in the August issue of the FASEB Journal.

The molecule temporarily disrupts connexin 43, a protein involved in cell communication. FirstString is now testing alphaCT1 in Phase III trials for bilateral breast surgery patients. Beyond this, the company explores its potential in chronic wound healing, radiation therapy wounds, and corneal repair. With $55 million raised across multiple funding rounds, FirstString Research continues advancing alphaCT1. The drug’s ability to reshape collagen offers a promising solution for surgical scars and other wound-healing applications. Phase III trials will further assess its effectiveness in clinical settings.